Strategies to reduce hepatitis C virus recurrence after liver transplantation (Q22305418)

From Wikidata

Jump to navigation Jump to search

The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.

scientific article

Language	Label	Description	Also known as
English	Strategies to reduce hepatitis C virus recurrence after liver transplantation	scientific article

Statements

scholarly article

0 references

Strategies to reduce hepatitis C virus recurrence after liver transplantation (English)

0 references

0 references

liver transplantation

1 reference

based on heuristic

inferred from title

Hepatitis C virus

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Ruben Ciria

1

author given names

Ruben

author last names

Ciria

1 reference

PubMed publication ID

8 February 2023

María Pleguezuelo

2

author given names

María

author last names

Pleguezuelo

1 reference

PubMed publication ID

8 February 2023

Shirin Elizabeth Khorsandi

3

author given names

Shirin Elizabeth

author last names

Khorsandi

1 reference

PubMed publication ID

8 February 2023

Diego Davila

4

author given names

Diego

author last names

Davila

1 reference

PubMed publication ID

8 February 2023

Abid Suddle

5

author given names

Abid

author last names

Suddle

1 reference

PubMed publication ID

8 February 2023

Hector Vilca-Melendez

6

author given names

Hector

author last names

Vilca-Melendez

1 reference

PubMed publication ID

8 February 2023

Sebastian Rufian

7

author given names

Sebastian

author last names

Rufian

1 reference

PubMed publication ID

8 February 2023

Manuel de la Mata

8

author given names

Manuel

author last names

de la Mata

1 reference

PubMed publication ID

8 February 2023

Javier Briceño

9

author given names

Javier

author last names

Briceño

1 reference

PubMed publication ID

8 February 2023

Pedro López Cillero

10

author given names

Pedro López

author last names

Cillero

1 reference

PubMed publication ID

8 February 2023

Nigel Heaton

11

author given names

Nigel

author last names

Heaton

1 reference

PubMed publication ID

8 February 2023

language of work or name

0 references

publication date

27 May 2013

0 references

World Journal of Hepatology

1 reference

5

0 references

5

0 references

237-50

0 references

Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3664282

19 March 2017

Antiviral prophylactic intervention for chronic hepatitis C virus in patients undergoing liver transplantation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3664282

19 March 2017

Antiviral therapy for recurrent liver graft infection with hepatitis C virus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3664282

19 March 2017

Adoptive immunotherapy with liver allograft–derived lymphocytes induces anti-HCV activity after liver transplantation in humans and humanized mice

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3664282

19 March 2017

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3664282

19 March 2017

Hepatitis C virus infection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3664282

19 March 2017

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3664282

7 April 2017

The IL-28 Genotype: How It Will Affect the Care of Patients with Hepatitis C Virus Infection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3664282

27 September 2017

New antiviral therapies for chronic hepatitis C

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3664282

27 September 2017

IL28B SNP rs8099917 is strongly associated with pegylated interferon-α and ribavirin therapy treatment failure in HCV/HIV-1 coinfected patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3664282

27 September 2017

Impact of human leukocyte antigen mismatching on outcomes of liver transplantation: a meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3664282

27 September 2017

Telaprevir for previously treated chronic HCV infection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3664282

27 September 2017

Review article: specifically targeted anti-viral therapy for hepatitis C - a new era in therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3664282

27 September 2017

Natural history of post-liver transplantation hepatitis C: A review of factors that may influence its course.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3664282

27 September 2017

Antiviral therapy of chronic hepatitis C in patients with advanced liver disease and after liver transplantation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3664282

27 September 2017

Microvesicular liver graft steatosis as a risk factor of initial poor function in relation to suboptimal donor parameters

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3664282

27 September 2017

An escalating dose regimen of pegylated interferon and ribavirin in HCV cirrhotic patients referred for liver transplant.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3664282

27 September 2017

The natural history of recurrent hepatitis C and what influences this

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3664282

27 September 2017

Hepatitis C therapy before and after liver transplantation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3664282

27 September 2017

Effect of ischemia-reperfusion on the incidence of acute cellular rejection and timing of histologic hepatitis C virus recurrence after liver transplantation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3664282

27 September 2017

Comparison of hepatitis C histological recurrence rates and patient survival between split and deceased donor liver transplantation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3664282

27 September 2017

Immunosuppression with calcineurin inhibitors with respect to the outcome of HCV recurrence after liver transplantation: results of a meta-analysis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3664282

27 September 2017

Ribavirin-induced anemia: mechanisms, risk factors and related targets for future research.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3664282

27 September 2017

Treating hepatitis C infection in liver transplant recipients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3664282

27 September 2017

Characterization of the hepatitis C virus E2 epitope defined by the broadly neutralizing monoclonal antibody AP33.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3664282

27 September 2017

Is retransplantation an option for recurrent hepatitis C cirrhosis after liver transplantation?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3664282

27 September 2017

Specific inhibition of hepatitis C virus replication by cyclosporin A.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3664282

27 September 2017

Impact of immunosuppression on immunopathogenesis of liver damage in hepatitis C virus-infected recipients following liver transplantation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3664282

27 September 2017

Report of the first International Liver Transplantation Society expert panel consensus conference on liver transplantation and hepatitis C.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3664282

27 September 2017

Natural history of hepatitis C and outcomes following liver transplantation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3664282

27 September 2017

Clinical experience gained from the use of 120 steatotic donor livers for orthotopic liver transplantation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3664282

27 September 2017

Treatment of patients with hepatitis C and cirrhosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3664282

27 September 2017

Advancing donor liver age and rapid fibrosis progression following transplantation for hepatitis C

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3664282

27 September 2017

A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus-infected patients awaiting liver transplantation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3664282

27 September 2017

Prediction of liver allograft fibrosis after transplantation for hepatitis C virus: persistent elevation of serum transaminase levels versus necroinflammatory activity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3664282

27 September 2017

Use of livers with microvesicular fat safely expands the donor pool

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3664282

27 September 2017

The difference in the fibrosis progression of recurrent hepatitis C after live donor liver transplantation versus deceased donor liver transplantation is attributable to the difference in donor age.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3664282

30 May 2018

Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3664282

30 May 2018

Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3664282

30 May 2018

Natural history of clinically compensated hepatitis C virus-related graft cirrhosis after liver transplantation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3664282

30 May 2018

Increased risk of type 2 diabetes in noncirrhotic patients with chronic hepatitis C virus infection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3664282

30 May 2018

Predictors of patient and graft survival following liver transplantation for hepatitis C.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3664282

30 May 2018

Long-term outcome of hepatitis C infection after liver transplantation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3664282

30 May 2018

Inhibitory effects of zidovudine in erythroid progenitor cells. Reversal with a combination of erythropoietin and interleukin-3.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3664282

30 May 2018

Virology and pathogenesis of hepatitis C virus recurrence.

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V5.I5.237

21 January 2018

Timing of reinfection and mechanisms of hepatocellular damage in transplanted hepatitis C virus-reinfected liver

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V5.I5.237

21 January 2018

A longitudinal analysis of hepatitis C virus replication following liver transplantation

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V5.I5.237

21 January 2018

Impact of the recurrence of hepatitis C virus infection after liver transplantation on the long-term viability of the graft

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V5.I5.237

21 January 2018

Antiviral therapy in HCV-infected cirrhotics awaiting liver transplantation: A costly strategy for mixed virological results

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V5.I5.237

21 January 2018

Peginterferon alpha-2b plus ribavirin for treatment of chronic hepatitis C with severe fibrosis: a multicentre randomized controlled trial comparing two doses of peginterferon alpha-2b.

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V5.I5.237

21 January 2018

Antiviral therapy of patients with decompensated cirrhosis to prevent recurrence of hepatitis C after liver transplantation.

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V5.I5.237

21 January 2018

Peginterferon alfa-2b and ribavirin in patients with hepatitis C virus and decompensated cirrhosis: a controlled study.

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V5.I5.237

21 January 2018

Peg-interferon alone or combined with ribavirin in HCV cirrhosis with portal hypertension: a randomized controlled trial.

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V5.I5.237

21 January 2018

Antiviral therapy increases the risk of bacterial infections in HCV-infected cirrhotic patients awaiting liver transplantation: A retrospective study.

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V5.I5.237

21 January 2018

Infection with chronic hepatitis C virus and liver transplantation: a role for interferon therapy before transplantation.

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V5.I5.237

21 January 2018

HCV-related advanced fibrosis/cirrhosis: randomized controlled trial of pegylated interferon alpha-2a and ribavirin

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V5.I5.237

21 January 2018

Safety, tolerability, and efficacy of pegylated-interferon alfa-2a plus ribavirin in HCV-related decompensated cirrhotics

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V5.I5.237

21 January 2018

European collaborative study on factors influencing outcome after liver transplantation for hepatitis C. European Concerted Action on Viral Hepatitis (EUROHEP) Group.

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V5.I5.237

21 January 2018

Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V5.I5.237

21 January 2018

Cost-effectiveness of hematologic growth factors for anemia occurring during hepatitis C combination therapy

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V5.I5.237

21 January 2018

Neutropenia during combination therapy of interferon alfa and ribavirin for chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V5.I5.237

21 January 2018

Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients.

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V5.I5.237

21 January 2018

Immunosuppression and donor age with respect to severity of HCV recurrence after liver transplantation

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V5.I5.237

21 January 2018

Differential effects of donor age in liver transplant recipients infected with hepatitis B, hepatitis C and without viral hepatitis.

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V5.I5.237

21 January 2018

Worse recent efficacy of antiviral therapy in liver transplant recipients with recurrent hepatitis C: impact of donor age and baseline cirrhosis.

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V5.I5.237

21 January 2018

Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V5.I5.237

21 January 2018

Mild donor liver steatosis has no impact on hepatitis C virus fibrosis progression following liver transplantation.

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V5.I5.237

21 January 2018

Donor livers with steatosis are safe to use in hepatitis C virus-positive recipients.

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V5.I5.237

21 January 2018

Impact of donor graft steatosis on overall outcome and viral recurrence after liver transplantation for hepatitis C virus cirrhosis

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V5.I5.237

21 January 2018

Impact of the donor liver with steatosis in patients with hepatitis C virus: not so FAst

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V5.I5.237

21 January 2018

Hepatitis C recurrence is not associated with allograft steatosis within the first year after liver transplantation

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V5.I5.237

21 January 2018

Histologic recurrence of chronic hepatitis C virus in patients after living donor and deceased donor liver transplantation

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V5.I5.237

21 January 2018

Living donor liver transplantation for hepatitis C-related cirrhosis: no difference in histological recurrence when compared to deceased donor liver transplantation recipients

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V5.I5.237

21 January 2018

Hepatitis C recurrence and fibrosis progression are not increased after living donor liver transplantation: a single-center study of 289 patients.

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V5.I5.237

21 January 2018

Transplantation of hepatitis C-positive livers in hepatitis C-positive patients is equivalent to transplanting hepatitis C-negative livers

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V5.I5.237

21 January 2018

Interactions between cytomegalovirus, human herpesvirus-6, and the recurrence of hepatitis C after liver transplantation

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V5.I5.237

21 January 2018

Impact of cytomegalovirus infection, year of transplantation, and donor age on outcomes after liver transplantation for hepatitis C.

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V5.I5.237

21 January 2018

Survival and recurrence of hepatitis C after liver transplantation in patients coinfected with human immunodeficiency virus and hepatitis C virus

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V5.I5.237

21 January 2018

Contribution of marginal donors to liver transplantation for hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V5.I5.237

21 January 2018

Influence of donor/recipient HLA-matching on outcome and recurrence of hepatitis C after liver transplantation

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V5.I5.237

21 January 2018

Long-term outcome of human leukocyte antigen mismatching in liver transplantation: results of the National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V5.I5.237

21 January 2018

Liver transplantation from an identical twin without immunosuppression, with early recurrence of hepatitis C.

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V5.I5.237

21 January 2018

Allograft TNFbeta and IL16 polymorphisms influence HCV recurrence and severity after liver transplantation

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V5.I5.237

21 January 2018

Pretransplantation CD56(+) innate lymphocyte populations associated with severity of hepatitis C virus recurrence

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V5.I5.237

21 January 2018

Natural killer cells play divergent roles in shaping the outcome of hepatitis C virus recurrence following liver transplantation

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V5.I5.237

21 January 2018

Natural killer cells in hepatitis C virus recurrence following liver transplantation: what role do they play?

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V5.I5.237

21 January 2018

The impact of diabetes mellitus on fibrosis progression in patients transplanted for hepatitis C.

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V5.I5.237

21 January 2018

Insulin resistance, serum adipokines and risk of fibrosis progression in patients transplanted for hepatitis C.

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V5.I5.237

21 January 2018

Influence of immunosuppression and effect of hepatitis C virus on new onset of diabetes mellitus in liver transplant recipients.

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V5.I5.237

21 January 2018

Preliminary results of a "prope" tolerogenic regimen with thymoglobulin pretreatment and hepatitis C virus recurrence in liver transplantation

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V5.I5.237

21 January 2018

Preventing hepatitis C virus recurrence in liver transplant recipients: a role for adoptive immunotherapy?

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V5.I5.237

21 January 2018

Prevalent immunosuppressive strategies in liver transplantation for hepatitis C: results of a multi-center international survey

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V5.I5.237

21 January 2018

Significant improvement in the outcome of HCV-infected transplant recipients by avoiding rapid steroid tapering and potent induction immunosuppression.

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V5.I5.237

21 January 2018

Influence of steroids on HCV recurrence after liver transplantation: A prospective study

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V5.I5.237

21 January 2018

Steroid avoidance in liver transplantation: meta-analysis and meta-regression of randomized trials

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V5.I5.237

21 January 2018

Results of lis2t, a multicenter, randomized study comparing cyclosporine microemulsion with C2 monitoring and tacrolimus with C0 monitoring in de novo liver transplantation

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V5.I5.237

21 January 2018

Cyclosporine suppresses hepatitis C virus in vitro and increases the chance of a sustained virological response after liver transplantation.

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V5.I5.237

21 January 2018

The use of cyclosporine for recurrent hepatitis C after liver transplant: a randomized pilot study

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V5.I5.237

21 January 2018

Structural features of envelope proteins on hepatitis C virus-like particles as determined by anti-envelope monoclonal antibodies and CD81 binding

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V5.I5.237

21 January 2018

Monoclonal antibody HCV-AbXTL68 in patients undergoing liver transplantation for HCV: results of a phase 2 randomized study

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V5.I5.237

21 January 2018

A randomized, open-label study to evaluate the safety and pharmacokinetics of human hepatitis C immune globulin (Civacir) in liver transplant recipients

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V5.I5.237

21 January 2018

Efficacy of antiviral therapy on hepatitis C recurrence after liver transplantation: a randomized controlled study.

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V5.I5.237

21 January 2018

Hepatitis C recurrence is more severe after living donor compared to cadaveric liver transplantation

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V5.I5.237

21 January 2018

Timing of hepatitis C antiviral therapy in patients with advanced liver disease: a decision analysis model

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3664282

29 November 2018

Long-term outcome of liver transplants for chronic hepatitis C: a 10-year follow-up

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3664282

29 November 2018

Combined interferon alpha2b and cyclosporin A in the treatment of chronic hepatitis C: controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3664282

29 November 2018

Severe or multiple rejection episodes are associated with early recurrence of hepatitis C after orthotopic liver transplantation.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3664282

29 November 2018

Transient elastography for diagnosis of advanced fibrosis and portal hypertension in patients with hepatitis C recurrence after liver transplantation

1 reference

https://pubmed.ncbi.nlm.nih.gov/23717735

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Donor age affects fibrosis progression and graft survival after liver transplantation for hepatitis C

1 reference

https://pubmed.ncbi.nlm.nih.gov/23717735

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The significance of metabolic syndrome in the setting of recurrent hepatitis C after liver transplantation

1 reference

https://pubmed.ncbi.nlm.nih.gov/23717735

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Insulin and insulin-like growth factor-1 stimulate proliferation and type I collagen accumulation by human hepatic stellate cells: differential effects on signal transduction pathways

1 reference

https://pubmed.ncbi.nlm.nih.gov/23717735

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Role of cytokine gene polymorphism in hepatitis C recurrence and allograft rejection among liver transplant recipients

1 reference

https://pubmed.ncbi.nlm.nih.gov/23717735

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Recurrent hepatitis C posttransplant: early preservation injury may predict poor outcome

1 reference

https://pubmed.ncbi.nlm.nih.gov/23717735

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Hepatic steatosis: a specific sign of hepatitis C reinfection after liver transplantation

1 reference

https://pubmed.ncbi.nlm.nih.gov/23717735

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

HLA-DRB1 Donor-Recipient Mismatch Affects the Outcome of Hepatitis C Disease Recurrence After Liver Transplantation

1 reference

https://pubmed.ncbi.nlm.nih.gov/23717735

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Living donor and split-liver transplants in hepatitis C recipients: does liver regeneration increase the risk for recurrence?

1 reference

https://pubmed.ncbi.nlm.nih.gov/23717735

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Assignment of steatotic livers by the Mayo model for end-stage liver disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/23717735

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Impact of donor age on survival and fibrosis progression in patients with hepatitis C undergoing liver transplantation using HCV+ allografts

1 reference

https://pubmed.ncbi.nlm.nih.gov/23717735

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Outcomes of liver transplantation in HIV-infected individuals: the impact of HCV and HBV infection

1 reference

https://pubmed.ncbi.nlm.nih.gov/23717735

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Liver Transplantation and Hepatitis C. Proceedings of a consensus development symposium

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V5.I5.237

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.4254/WJH.V5.I5.237

0 references

PMC publication ID

0 references

PubMed publication ID

0 references

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q22305418&oldid=1958245275"